Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + tremelimumab + lenvatinib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Durvalumab + tremelimumab + lenvatinib** is an experimental combination regimen being investigated for the treatment of unresectable hepatocellular carcinoma. Durvalumab is a human monoclonal antibody that blocks PD-L1, enhancing anti-tumor T-cell responses. Tremelimumab is a human monoclonal antibody targeting CTLA-4, also enhancing immune activation against tumors. Lenvatinib is an oral small molecule inhibitor targeting multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFRα, RET, and KIT, impeding tumor angiogenesis and proliferation. This combination aims to synergistically stimulate immune-mediated anti-tumor effects while inhibiting angiogenesis. The combination is being tested in several phase II and III clinical trials in patients with hepatocellular carcinoma, typically for those with previously untreated unresectable disease[2][3][5][7][9][10].
- Other names
- durvalumab + tremelimumab + lenvatinibImfinzi + Imjudo + LenvimaImfinzi + tremelimumab + lenvatinibSTRIDE + lenvatinibSTRIDE regimen + lenvatinib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on durvalumab + tremelimumab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + tremelimumab + lenvatinib.